Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA
Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Temozolomide (Temodar) for Treatment of Newly Diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma
Sponsor: Feinstein Institute for Medical Research
A PHASE1 clinical study on Anaplastic Astrocytoma and Glioblastoma Multiforme, this trial is completed. The trial is conducted by Feinstein Institute for Medical Research and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 4 earlier versions
-
Jun 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Feinstein Institute for Medical Research
- Hofstra North Shore
- Northwell Health
For direct contact, visit the study record on ClinicalTrials.gov .